Table 2.
Average and standard deviation of MMSE scores by ATN group at baseline and follow-up, and percentage of subjects with significant cognitive decline by profile. Fourth row contains p-values from paired Wilcoxon tests between baseline and follow-up MMSE scores by group. Fifth row shows numbers of subjects that declined at follow-up and the percentage of decliners for each profile. Last column displays p-values from the Kruskal-Wallis ANOVA comparing MMSE scores by time points. Superscript letters indicate groups showing significant differences at post hoc comparisons using Dunn tests with Benjamin-Hochberg correction for multiple comparisons: a > b, c > d
| ATN Groups | Normal (n = 35) |
AD-PC (n = 24) |
AD-P (n = 42) |
SNAP (n = 7) |
p-value |
|---|---|---|---|---|---|
| Baseline | 28 ± 2a | 27 ± 3c | 24 ± 5b,d | 25 ± 6b | < 0.01 |
| Follow-up | 28 ± 2a | 26 ± 3c | 21 ± 8b,d | 22 ± 9b | < 0.01 |
| p-value | 0.55 | < 0.01 | < 0.01 | 0.10 | - |
| n Decliners (%) | 7 (20) | 9 (38) | 23 (55) | 3 (43) | - |
| Cox model | 1 (reference) |
3.16 [1.17–8.52] |
6.15 [2.59–14.59] |
n.s | - |
Abbreviations: A, amyloid; T, tau; N, neurodegeneration; n, number of subjects; n.s., not significant; AD, Alzheimer’s disease; AD-PC, AD pathological change; AD-P, AD pathology; SNAP, suspected non-AD pathology